Ipsen will acquire Kartos for up to $1.75 billion

Golden Ten Data, June 29 — Ipsen announced that it has agreed to acquire Kartos Therapeutics in a deal valued at up to $1.75 billion, aiming to strengthen the French pharmaceutical company's pipeline of cancer drugs. According to Ipsen, under the agreement, the company will make an upfront payment of $450 million to acquire Kartos, with up to an additional $1.3 billion contingent on regulatory and sales milestones. Ipsen stated that the acquisition of the unlisted Kartos will bring navtemadlin into its late-stage oncology pipeline. This candidate drug is used for the treatment of myelofibrosis, a rare blood cancer, and is currently in late-stage clinical trials. The company added that the transaction is expected to be completed by the end of the third quarter, subject to customary closing conditions.